Literature DB >> 23994889

HLA-peptide multimer selection of adenovirus-specific T cells for adoptive T-cell therapy.

Geothy Chakupurakal1, David Onion, Sarah Bonney, Mark Cobbold, Vivien Mautner, Paul Moss.   

Abstract

Adenovirus (Ad) infection is a cause of significant morbidity and mortality in hematopoietic stem cell transplant recipients and virus-specific immunotherapy is one option for improved control. Cellular immunity is an important component in suppression of Ad replication but the frequency and population distribution of Ad-specific CD8 T cells has not been systematically investigated. This is an important question in relation to the potential use of these cells for adoptive transfer. To address this question, HLA-peptide multimers were generated for 8 HLA class I-restricted Ad epitopes, which are highly conserved across Ad species. Epitope-specific CD8 T cells from healthy donors were identified by tetramer staining and HLA class I A*01-restricted TDL peptide staining T cells were characterized in relation to frequency, phenotype, and function. The cells demonstrated a minimally differentiated central memory phenotype (CD45RA, CD45RO, CCR7, CD62L, CD27, CD28, and CD57) and were able to produce IFN-γ and proliferate extensively upon antigen stimulation in vitro. After proliferation, the phenotype switched to CD45RO, although it is interesting to note that CCR7 expression was retained. Despite their low frequency, tetramer-staining cells could be enriched with magnetic bead technology. Their characteristics should permit rapid establishment in vivo post adoptive transfer, increasing therapeutic options for patients with Ad infection. This is the first reported characterization of Ad-specific tetramer-staining T cells with a view to adoptive transfer to hematopoietic stem cell transplant patients with Ad infection. The efficacy of these cells needs to be further evaluated in the setting of a clinical trial.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23994889     DOI: 10.1097/CJI.0b013e3182a8029e

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

Review 1.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Contributions of CD8 T cells to the pathogenesis of mouse adenovirus type 1 respiratory infection.

Authors:  Caitlyn T Molloy; Jennifer S Andonian; Harrison M Seltzer; Megan C Procario; Michael E Watson; Jason B Weinberg
Journal:  Virology       Date:  2017-04-11       Impact factor: 3.616

Review 3.  Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections.

Authors:  R J O'Reilly; S Prockop; A N Hasan; G Koehne; E Doubrovina
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

4.  Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.

Authors:  Rachel S Cooper; Alasdair R Fraser; Linda Smith; Paul Burgoyne; Stuart N Imlach; Lisa M Jarvis; David M Turner; Sharon Zahra; Marc L Turner; John D M Campbell
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

5.  Molecular Characteristics of Human Adenovirus Type 3 Circulating in Parts of China During 2014-2018.

Authors:  Yali Duan; Baoping Xu; Changchong Li; Yixiao Bao; Shuhua An; Yunlian Zhou; Aihuan Chen; Li Deng; Limin Ning; Yun Zhu; Wei Wang; Meng Zhang; Lili Xu; Xiangpeng Chen; Zhengde Xie
Journal:  Front Microbiol       Date:  2021-06-29       Impact factor: 5.640

6.  Prostaglandin E2 Production and T Cell Function in Mouse Adenovirus Type 1 Infection following Allogeneic Bone Marrow Transplantation.

Authors:  Mary K McCarthy; Megan C Procario; Carol A Wilke; Bethany B Moore; Jason B Weinberg
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

Review 7.  Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Kevin Sheng-Kai Ma; Chien-Chang Lee; Ko-Jiunn Liu; James Cheng-Chung Wei; Yuan-Ti Lee; Li-Tzu Wang
Journal:  Pathogens       Date:  2021-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.